miércoles, 19 de agosto de 2015

Mycobacterium abscessus Complex Infections in Humans - Volume 21, Number 9—September 2015 - Emerging Infectious Disease journal - CDC

FULL-TEXT ►

Mycobacterium abscessus Complex Infections in Humans - Volume 21, Number 9—September 2015 - Emerging Infectious Disease journal - CDC





Volume 21, Number 9—September 2015

CME ACTIVITY - Synopsis

Mycobacterium abscessus Complex Infections in Humans

Meng-Rui Lee, Wang-Huei Sheng, Chien-Ching Hung, Chong-Jen Yu, Li-Na Lee, and Po-Ren HsuehComments to Author 
Author affiliations: National Taiwan University Hospital Hsin-Chu Branch, Hsin-Chu, Taiwan (M.-R. Lee, W.-H. Sheng, C.-C. Hung, C.-J. Yu, L.-N. Lee, P.-R. Hsueh)National Taiwan University Hospital, Taipei, Taiwan (M.-R. Lee, W.-H. Sheng, C.-C. Hung, C.-J. Yu, L.-N. Lee, P.-R. Hsueh)

Abstract

Mycobacterium abscessus complex comprises a group of rapidly growing, multidrug-resistant, nontuberculous mycobacteria that are responsible for a wide spectrum of skin and soft tissue diseases, central nervous system infections, bacteremia, and ocular and other infections. M. abscessus complex is differentiated into 3 subspecies: M. abscessus subsp. abscessus, M. abscessus subsp. massiliense, and M. abscessus subsp. bolletii. The 2 major subspecies, M. abscessus subsp. abscessus and M. abscessus subsp.massiliense, have different erm(41) gene patterns. This gene provides intrinsic resistance to macrolides, so the different patterns lead to different treatment outcomes. M. abscessus complex outbreaks associated with cosmetic procedures and nosocomial transmissions are not uncommon. Clarithromycin, amikacin, and cefoxitin are the current antimicrobial drugs of choice for treatment. However, new treatment regimens are urgently needed, as are rapid and inexpensive identification methods and measures to contain nosocomial transmission and outbreaks.
Mycobacteria are divided into 2 major groups for the purpose of diagnosis and treatment: Mycobacterium tuberculosis complex, which comprises M. tuberculosis, and nontuberculous mycobacteria (NTM), which comprise all of the other mycobacteria species that do not cause tuberculosis. NTM can cause pulmonary disease resembling tuberculosis, skin and soft tissue infections (SSTIs), central nervous system infections, bacteremia, and ocular and other infections (1,2). Over the past decade, the number of NTM disease cases worldwide has markedly increased (3,4), and the upsurge cannot be explained solely by increased awareness among physicians and advances in laboratory methods (3).
M. abscessus complex is a group of rapidly growing, multidrug-resistant NTM species that are ubiquitous in soil and water (1). Species comprising M. avium complex (MAC) are the most common NTM species responsible for disease; however, infections caused by M. abscessus complex are more difficult to treat because of antimicrobial drug resistance (5). M. abscessus complex is also resistant to disinfectants and, therefore, can cause postsurgical and postprocedural infections (2,5). Although M. abscessus complex most commonly causes SSTIs and pulmonary infections, the complex can also cause disease in almost all human organs (2,5). To improve our understanding ofM. abscessus complex infections, we reviewed the epidemiology and clinical features of and treatment and prevention measure for diseases caused by the organisms as well as the taxonomy and antimicrobial susceptibilities of these organisms.
Dr. Lee is attending physician at the Department of Internal Medicine, National Taiwan University Hospital Hsin-Chu Branch, Hsin-Chu, Taiwan, and Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan. His primary research interests include emerging infections and epidemiologic and clinical research on diseases caused by nontuberculous mycobacteria.

References

  1. Brown-Elliott BAWallace RJ JrClinical and taxonomic status of pathogenic nonpigmented or late-pigmenting rapidly growing mycobacteria. Clin Microbiol Rev2002;15:71646DOIPubMed
  2. Griffith DEAksamit TBrown-Elliott BACatanzaro ADaley CGordin FAn official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med2007;175:367416DOIPubMed
  3. Marras TKMendelson DMarchand-Austin AMay KJamieson FBPulmonary nontuberculous mycobacterial disease, Ontario, Canada, 1998–2010. Emerg Infect Dis2013;19:188991DOIPubMed
  4. Lai CCTan CKChou CHHsu HLLiao CHHuang YTIncreasing incidence of nontuberculous mycobacteria, Taiwan, 2000–2008. Emerg Infect Dis.2010;16:2946DOIPubMed
  5. Nessar RCambau EReyrat JMMurray AGicquel BMycobacterium abscessus: a new antibiotic nightmare. J Antimicrob Chemother.2012;67:8108DOIPubMed
  6. Leao SCTortoli EEuzeby JPGarcia MJProposal that Mycobacterium massiliense and Mycobacterium bolletii be united and reclassified asMycobacterium abscessus subsp. bolletii comb. nov., designation of Mycobacterium abscessus subsp. abscessus subsp. nov. and emended description of Mycobacterium abscessus. Int J Syst Evol Microbiol2011;61:23113DOIPubMed
  7. Benwill JLWallace RJ JrMycobacterium abscessus: challenges in diagnosis and treatment. Curr Opin Infect Dis2014;27:50610DOIPubMed
  8. Choo SWWee WYNgeow YFMitchell WTan JLWong GJGenomic reconnaissance of clinical isolates of emerging human pathogenMycobacterium abscessus reveals high evolutionary potential. Sci Rep. 2014;4:4061.
  9. Cho YJYi HChun JCho SNDaley CLKoh WJThe genome sequence of ‘Mycobacterium massiliense’ strain CIP 108297 suggests the independent taxonomic status of the Mycobacterium abscessus complex at the subspecies level. PLoS ONE2013;8:e81560DOIPubMed
  10. Sassi MDrancourt MGenome analysis reveals three genomospecies in Mycobacterium abscessus. BMC Genomics2014;15:359DOIPubMed
  11. Heydari HWee WYLokanathan NHari RMohamed Yusoff ABeh CYMabsBase: a Mycobacterium abscessus genome and annotation database.PLoS ONE2013;8:e62443DOIPubMed
  12. Teng SHChen CMLee MRLee TFChien KYTeng LJMatrix-assisted laser desorption ionization–time of flight mass spectrometry can accurately differentiate between Mycobacterium masilliense (M. abscessus subspecies bolletti) and M. abscessus (sensu stricto). J Clin Microbiol.2013;51:31136DOIPubMed
  13. Prevots DRShaw PAStrickland DJackson LARaebel MABlosky MANontuberculous mycobacterial lung disease prevalence at four integrated health care delivery systems. Am J Respir Crit Care Med2010;182:9706DOIPubMed
  14. Lee MRYang CYChang KPKeng LTYen DHWang JYFactors associated with lung function decline in patients with non-tuberculous mycobacterial pulmonary disease. PLoS ONE2013;8:e58214DOIPubMed
  15. Levy IGrisaru-Soen GLerner-Geva LKerem EBlau HBentur LMulticenter cross-sectional study of nontuberculous mycobacterial infections among cystic fibrosis patients, Israel. Emerg Infect Dis2008;14:37884DOIPubMed
  16. Jeon KKwon OJLee NYKim BJKook YHLee SHAntibiotic treatment of Mycobacterium abscessus lung disease: a retrospective analysis of 65 patients. Am J Respir Crit Care Med2009;180:896902 . DOIPubMed
  17. Jarand JLevin AZhang LHuitt GMitchell JDDaley CLClinical and microbiologic outcomes in patients receiving treatment for Mycobacterium abscessus pulmonary disease. Clin Infect Dis2011;52:56571DOIPubMed
  18. Koh WJJeon KLee NYKim BJKook YHLee SHClinical significance of differentiation of Mycobacterium massiliense from Mycobacterium abscessus. Am J Respir Crit Care Med2011;183:40510DOIPubMed
  19. Kothavade RJDhurat RSMishra SNKothavade URClinical and laboratory aspects of the diagnosis and management of cutaneous and subcutaneous infections caused by rapidly growing mycobacteria. Eur J Clin Microbiol Infect Dis2013;32:16188 . DOIPubMed
  20. Nakanaga KHoshino YEra YMatsumoto KKanazawa YTomita AMultiple cases of cutaneous Mycobacterium massiliense infection in a “hot spa” in Japan. J Clin Microbiol2011;49:6137DOIPubMed
  21. Lee MRCheng ALee YCYang CYLai CCHuang YTCNS infections caused by Mycobacterium abscessus complex: clinical features and antimicrobial susceptibilities of isolates. J Antimicrob Chemother2012;67:2225DOIPubMed
  22. Shields RKClancy CJMinces LRShigemura NKwak EJSilveira FPEpidemiology and outcomes of deep surgical site infections following lung transplantation. Am J Transplant2013;13:213745DOIPubMed
  23. Browne SKBurbelo PDChetchotisakd PSuputtamongkol YKiertiburanakul SShaw PAAdult-onset immunodeficiency in Thailand and Taiwan. N Engl J Med2012;367:72534DOIPubMed
  24. El Helou GViola GMHachem RHan XYRaad IIRapidly growing mycobacterial bloodstream infections. Lancet Infect Dis2013;13:16674.DOIPubMed
  25. El Helou GHachem RViola GMEl Zakhem AChaftari AMJiang YManagement of rapidly growing mycobacterial bacteremia in cancer patients.Clin Infect Dis2013;56:8436DOIPubMed
  26. Lee MRKo JCLiang SKLee SWYen DHHsueh PRBacteraemia caused by Mycobacterium abscessus subsp. abscessus and M. abscessus subsp.bolletii: clinical features and susceptibilities of the isolates. Int J Antimicrob Agents2014;43:43841DOIPubMed
  27. Girgis DOKarp CLMiller DOcular infections caused by non-tuberculous mycobacteria: update on epidemiology and management. Clin Experiment Ophthalmol2012;40:46775DOIPubMed
  28. Moorthy RSValluri SRao NANontuberculous mycobacterial ocular and adnexal infections. Surv Ophthalmol2012;57:20235DOIPubMed
  29. Liu RTo KKTeng JLChoi GKMok KYLaw KIMycobacterium abscessus bacteremia after receipt of intravenous infusate of cytokine-induced killer cell therapy for body beautification and health boosting. Clin Infect Dis2013;57:98191DOIPubMed
  30. Bryant JMGrogono DMGreaves DFoweraker JRoddick IInns TWhole-genome sequencing to identify transmission of Mycobacterium abscessus between patients with cystic fibrosis: a retrospective cohort study. Lancet2013;381:155160DOIPubMed
  31. Viana-Niero CLima KVLopes MLRabello MCMarsola LRBrilhante VCMolecular characterization of Mycobacterium massiliense andMycobacterium bolletii in isolates collected from outbreaks of infections after laparoscopic surgeries and cosmetic procedures. J Clin Microbiol.2008;46:8505DOIPubMed
  32. Clinical and Laboratory Standards Institute (CLSI). Susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes. Approved standard—second edition. CLSI document M24–A2. Wayne (PA): The Institute; 2011.
  33. Adékambi TDrancourt MMycobacterium bolletii respiratory infections. Emerg Infect Dis2009;15:3025DOIPubMed
  34. Lee SHYoo HKKim SHKoh WJKim CKPark YKThe drug resistance profile of Mycobacterium abscessus group strains from Korea. Ann Lab Med.2014;34:31–7.
  35. Huang YCLiu MFShen GHLin CFKao CCLiu PYClinical outcome of Mycobacterium abscessus infection and antimicrobial susceptibility testing.J Microbiol Immunol Infect2010;43:4016DOIPubMed
  36. Brown-Elliott BAMann LBHail DWhitney CWallace RJ JrAntimicrobial susceptibility of nontuberculous mycobacteria from eye infections.Cornea2012;31:9006DOIPubMed
  37. Broda AJebbari HBeaton KMitchell SDrobniewski FComparative drug resistance of Mycobacterium abscessus and M. chelonae isolates from patients with and without cystic fibrosis in the United Kingdom. J Clin Microbiol2013;51:21723DOIPubMed
  38. Zhuo FLSun ZGLi CYLiu ZHCai LZhou CClinical isolates of Mycobacterium abscessus in Guangzhou area most possibly from the environmental infection showed variable susceptibility. Chin Med J (Engl)2013;126:187883 .PubMed
  39. Nash KABrown-Elliott BAWallace RJ JrA novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. Antimicrob Agents Chemother2009;53:136776DOIPubMed
  40. Thomson RMCarter RTolson CCoulter CHuygens FHargreaves MFactors associated with the isolation of nontuberculous mycobacteria (NTM) from a large municipal water system in Brisbane, Australia. BMC Microbiol2013;13:89DOIPubMed

Figures

Tables

Suggested citation for this article: Lee MR, Sheng WH, Hung CC, Yu CJ, Lee LN, Hsueh PR. Mycobacterium abscessus complex infections in humans. Emerg Infect Dis. 2015 Sep [date cited]. http://dx.doi.org/10.3201/eid2109.141634
DOI: 10.3201/eid2109.141634

No hay comentarios:

Publicar un comentario